

TP Upgrade to 1.35 (48% upside)
Acquisition of Shenzhen Sihuan will boost the top and bottom line growth.
On Oct 11, Sihuan entered into a sale and purchase agreement to acquire Shenzhen Sihuan Pharmaceutical from three independent parties for RMB 60 million. Shenzhen Sihuan is engaged in the marketing and distribution of 12 own-brand and 18 third-party pharmaceutical products within PRC, through a network of 29 sales offices and 1200 distributors. Among its drug portfolio, two highly promising drugs Ningxinao and Quao are drugs for cardio and vascular diseases. As some key drugs of Shenzhen Sihuan have successfully won bids in the Guangdong Online Tender and in Hubei Province, Shenzhen Sihuan will very likely show high growth in the second half of FY07 and FY08.
We slightly adjusted up the revenue and net profit for FY07 and FY08. We expect net profit growth of 93.1% and 34.1% for FY07 and FY08. Based on our FCFE model with a discount rate of 12% and terminal growth rate 2%, we derived a fair value of S$1.35, which is 15.6 times of forward twelve month earning and 13.5 times of FY08?s earnings. This fair value represents around 45% upside from the last closing price of S$0.925. Maintain BUY!
Singer88
Thank you so much for your useful info. Then will continue holding for a while.

PRESS RELEASE Sihuan Pharmaceutical buys Shenzhen pharmaceutical company for RMB60 million ? Adds 30 products to Sihuan?s existing portfolio of 33 products ? Enhances Sihuan?s position in the cardiocerebral vascular product market ? Acquisition cost amounts to a PE of 5x on 2007 earnings based on profit guarantee Singapore, 10 October 2007 ? Mainboard-listed Sihuan Pharmaceutical Holdings Group Ltd ( 四环医药控股集团有限公司 or ?Sihuan?), a leading manufacturer of cardiocerebral vascular drugs in the PRC, has agreed to buy Shenzhen Sihuan Pharmaceutical Co., Ltd (?Shenzhen Sihuan?) for RMB60 million.
Profit Guarantee
The Vendors undertake that the audited net profit after tax of Shenzhen Sihuan for the financial years ending 31 December 2007 and 2008 shall not be less than RMB 12million and RMB 16million respectively. In the event that the actual profit after tax is lower than the profit guarantees, the Vendors shall be liable to compensate Hainan Sihuan for any shortfall in the net profit by reducing or returning the Consideration proportionately.
0246 GMT [Dow Jones] STOCK CALL: Daiwa raises target price for Sihuan Pharmaceutical (BL5.SG) to S$1.25 from S$1.04, based on P/E of 15.4X earnings; "we expect continued strong earnings growth to boost the share price performance." Notes China-based drugmaker has maintained growth momentum from last year with 112% on-year surge in 1H07 net profit to CNY83 million, with strong sales of core product Kelinao; "there is still considerable room for Kelinao sales to expand, and do not see competition emerging for at least another two years." Tips earnings CAGR of over 50% in next 2 years. Keeps Buy call. Stock +2.9% at S$0.89. (FKH)
Curtis Bergh, 09 Oct 2007
Sihuan Pharmaceuticals has purchased the rights to a new tablet being developed that helps treat vertigo symptoms as a result of cardiovascular disease.
Sihuan acquired the rights from China's Academy of Military Medical Sciences for RMB 8 mln.
AMMS has applied to the PRC State Food and Drug Administration to classify the drug in Category 1 for approval to conduct clinical trials. Category 1 is the category in which drugs that have not been previously marketed in China or overseas are placed in.
The stock last traded at S$0.94, up S$0.08 or 8.67%.
Anyone has analyzed this counter? My studies showed the result is not so good, so I want to sell now, even I missed out the recent hight price @ 0.955$. Am I right? Please advise.
Have so many paper-loss counters on hand, only this one can help me make some profits. Don't want to lose more...... Thanks.
Is it too late to go in now. Any revised TP?
Thx.
Bro ,this 2 days it will cheong ;today Singapore GIC will buy this Counter.
HUAT lah.
This counter went up a bit the past few days ... anyone got any comments ?
More coverage by Houses to move in and sihuan potentially a multi-dollars stocks with good growth, still havent factor in the M&A, joint venture and New drugs patentship...
Not to miss now or have to trade it at more than $1plus or more later...
Note*: 'Jip' early, fruits bear fast and many many harvesting on the way.....
Daiwa targets $0.90 this morning!!!!!!!!!CHEONG AH!!!!!!!
We initiate coverage of Sihuan Pharmaceutical Holdings Group
(Sihuan) with a
S$0.90, based on a 15x PER on our earnings forecasts for 2007.
We expect strong earnings growth and positive news flow to
drive its share price over the next six months.
1 (Buy) rating and a six-month target price of·
manufacturing base in Beijing, is one of China?s leading
manufacturers of cardiocerebral vascular drugs, which are used
to treat diseases that affect the brain, heart and blood vessels.
The company carries 31 pharmaceutical products currently, and
has more than 50 products under research and development. Its
key product,
drug in China, with sales increasing by 93% YoY in 2006.
Sihuan, with its headquarters in Haikou, Hainan Province andKelinao, is the best-selling peripheral vasodilation·
2006, and by a further 72% YoY for 1Q07. For the full year, we
forecast Sihaun to record a 59% YoY increase in net profit to
Rmb143.5m, backed by continued strong demand for
Over the medium term, we expect the company to maintain its
growth momentum due to its expanding range of products and
rising demand for cardiocerebral vascular drugs in China.
Sihuan?s net profit rose at a CAGR of 72% between 2003 andKelinao.

